BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...B round include Partners Investment, Superstring Capital, Orion...
...Lake Bleu Capital, Partners Investment, Superstring Capital, Orion...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Parkinson's disease (PD): Zelapar selegiline from Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC); Eldepryl selegiline from Orion Corp....
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...ASA (OSE:PCIB) hired Amir Snapir as CMO. He was director of rare disease development at Orion Corp....
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

...EU approval for Orion, Bayer prostate cancer therapy The European Commission approved Nubeqa darolutamide from Orion Corp....
...to treat OA of the knee. BioCentury Staff Relumina (relugolix, TAK-385) idecabtagene vicleucel, ide-cel (bb2121) Gedeon Richter plc Myovant Sciences GmbH Orion Corp. Bayer...
BioCentury | Feb 1, 2020
Company News

Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations

...the committee’s other recommendations were androgen receptor inhibitor Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp....
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...not available (see Table: "Comparing PCSK9 Data"). A Phase III CV outcomes study of inclisiran, ORION-4...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...was associate VP, AAV platform at Rocket Pharmaceuticals Inc. (NASDAQ:RCKT). The chemogenetics company also promoted Orion...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...chief commercial officer. He was VP of business development at Banyan Biomarkers Inc. Biologics play Orion...
...Group Ltd. Insmed Inc. Yukin Therapeutics Pfenex Inc. EyePoint Pharmaceuticals Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion...
BioCentury | Sep 25, 2019
Clinical News

RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

...RNAi against PCSK9 met all primary and secondary endpoints in the Phase III ORION-9 and ORION-10...
...ORION-10 were "at least as favorable" as in previously announced results from the Phase III ORION-11...
...ORION-4 CV outcomes and ORION-5 homozygous familial hypercholesterolemia (HoFH) trials. Detailed data from ORION-9 and ORION-10...
BioCentury | Sep 3, 2019
Clinical News

RNAi therapy from Medicines Co., Alnylam cuts cholesterol by 54%, could compete with PCSK9 mAbs

...ORION-11 trial's primary and secondary endpoints (see "Inclisiran Clears First Phase III Hurdle" ). In ORION-11...
...patients with atherosclerotic CV disease (ASCVD). Data from two more Phase III studies, ORION-9 and ORION-10...
...FDA by year end, with a European submission to follow in 1Q20. Safety data from ORION-11...
Items per page:
1 - 10 of 341
BioCentury | Mar 31, 2021
Emerging Company Profile

Mega-round meets dealmaker as CBC’s AffaMed readies to build pipeline

...B round include Partners Investment, Superstring Capital, Orion...
...Lake Bleu Capital, Partners Investment, Superstring Capital, Orion...
BioCentury | Jul 31, 2020
Distillery Therapeutics

MAO-B, GABRA5 identified as astrocyte targets in subcortical stroke

...Parkinson's disease (PD): Zelapar selegiline from Bausch Health Companies Inc. (TSX:BHC; NYSE:BHC); Eldepryl selegiline from Orion Corp....
BioCentury | Apr 4, 2020
Management Tracks

CureVac names Stéphenne chairman; plus Desmond-Hellmann to Pfizer’s board, Reagan-Udall, Kyowa Kirin, Assembly, BioCryst and more

...ASA (OSE:PCIB) hired Amir Snapir as CMO. He was director of rare disease development at Orion Corp....
BioCentury | Apr 2, 2020
Product Development

April 1 Quick Takes: Gedeon gets Europe rights to Myovant’s uterine fibroid therapy following MAA submission; plus Orion-Bayer, BMS-bluebird, Mesoblast and more

...EU approval for Orion, Bayer prostate cancer therapy The European Commission approved Nubeqa darolutamide from Orion Corp....
...to treat OA of the knee. BioCentury Staff Relumina (relugolix, TAK-385) idecabtagene vicleucel, ide-cel (bb2121) Gedeon Richter plc Myovant Sciences GmbH Orion Corp. Bayer...
BioCentury | Feb 1, 2020
Company News

Alnylam’s Givlaari, Novo’s Rybelsus among CHMP’s latest recommendations

...the committee’s other recommendations were androgen receptor inhibitor Nubeqa darolutamide from Bayer AG (Xetra:BAYN) and Orion Corp....
BioCentury | Nov 26, 2019
Company News

After mid-decade makeover, Medicines Co. accepts Novartis' $9.7B bid on eve of inclisiran submission

...not available (see Table: "Comparing PCSK9 Data"). A Phase III CV outcomes study of inclisiran, ORION-4...
BioCentury | Nov 23, 2019
Company News

Management tracks: Sanofi head of strategy Mansuri set to retire; plus Arrakis, MorphoSys, Kymera, Kronos, Kite, Twist, Cerevel, Coda, Science 37, and more

...was associate VP, AAV platform at Rocket Pharmaceuticals Inc. (NASDAQ:RCKT). The chemogenetics company also promoted Orion...
BioCentury | Nov 16, 2019
Company News

Management tracks: Lonza CEO to step down; plus Arrowhead, Insmed, Inozyme, Yukin, Pfenex, EyePoint, Verseau, Abingworth, CBC, Flagship, Diverse, Theragnostics,

...chief commercial officer. He was VP of business development at Banyan Biomarkers Inc. Biologics play Orion...
...Group Ltd. Insmed Inc. Yukin Therapeutics Pfenex Inc. EyePoint Pharmaceuticals Inc. Verseau Therapeutics Inc. Flagship Pioneering Inozyme Pharma Inc. Theragnostics Ltd. Prescient Medicine Holdings Inc. Orion...
BioCentury | Sep 25, 2019
Clinical News

RNAi therapy hits cholesterol endpoints in two more Phase IIIs ahead of Medicines Co.'s submission

...RNAi against PCSK9 met all primary and secondary endpoints in the Phase III ORION-9 and ORION-10...
...ORION-10 were "at least as favorable" as in previously announced results from the Phase III ORION-11...
...ORION-4 CV outcomes and ORION-5 homozygous familial hypercholesterolemia (HoFH) trials. Detailed data from ORION-9 and ORION-10...
BioCentury | Sep 3, 2019
Clinical News

RNAi therapy from Medicines Co., Alnylam cuts cholesterol by 54%, could compete with PCSK9 mAbs

...ORION-11 trial's primary and secondary endpoints (see "Inclisiran Clears First Phase III Hurdle" ). In ORION-11...
...patients with atherosclerotic CV disease (ASCVD). Data from two more Phase III studies, ORION-9 and ORION-10...
...FDA by year end, with a European submission to follow in 1Q20. Safety data from ORION-11...
Items per page:
1 - 10 of 341